STOCK TITAN
  1. Home
  2. Sec-filings
  3. MDXH
  4. [Form 3] MDxHealth SA Initial Statement of Beneficial Ownership

MDxHealth (MDXH) director lists multi-year share option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

MDxHealth SA director Hilde Windels has filed an initial ownership report showing indirect holdings of share options in MDxHealth SA through Hilde Windels BV. The positions include options over 1,000 ordinary shares at €49.70 expiring on June 1, 2028 and 1,000 shares at €12.80 expiring on July 1, 2029. Additional grants cover 30,000 ordinary shares at $2.62 expiring on June 22, 2034 and 10,000 shares at $2.18 expiring on June 27, 2035. These options were granted in prior years and vest or vested in connection with annual general shareholders' meetings, and the reporting person disclaims beneficial ownership of securities held by Hilde Windels BV except to the extent of any pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Windels Hilde
Role Director
Type Security Shares Price Value
holding Share Option -- -- --
holding Share Option -- -- --
holding Share Option -- -- --
holding Share Option -- -- --
Holdings After Transaction: Share Option — 42,000 shares (Indirect, By Hilde Windels BV)
Footnotes (5)
  1. F1. Represents options to purchase 1,000 ordinary shares of the Issuer at a price per share of 49.70 Euros granted on June 1, 2018 which vested in full on the date of the annual general shareholders' meeting that took place in the calendar year following the calendar year in which the options were granted.
  2. F2. Shares held by Hilde Windels BV may be deemed to be beneficially owned by the Reporting Person as the Managing Director of Hilde Windels BV. The Reporting Person disclaims beneficial ownership of the securities held by Hilde Windels BV other than to the extent that she may have a pecuniary interest therein.
  3. F3. Represents options to purchase 1,000 ordinary shares of the Issuer at a price per share of 12.80 Euros granted on July 1, 2019 which vested in full on the date of the annual general shareholders' meeting that took place in the calendar year following the calendar year in which the options were granted.
  4. F4. Represents options to purchase 30,000 ordinary shares of the Issuer at a price per share of $2.62 granted on June 22, 2024 which vested in full on the date of the annual general shareholders' meeting that took place in the calendar year following the calendar year in which the options were granted.
  5. F5. Represents options to purchase 10,000 ordinary shares of the Issuer at a price per share of $2.18 granted on June 27, 2025 which vest in full on the date of the annual general shareholders' meeting that takes place in the calendar year following the calendar year in which the options were granted.
Option grant 2018 1,000 shares at €49.70 Options on ordinary shares expiring June 1, 2028
Option grant 2019 1,000 shares at €12.80 Options on ordinary shares expiring July 1, 2029
Option grant 2024 30,000 shares at $2.62 Options on ordinary shares expiring June 22, 2034
Option grant 2025 10,000 shares at $2.18 Options on ordinary shares expiring June 27, 2035
Share Option financial
"security_title: "Share Option""
Ordinary Shares financial
"underlying_security_title: "Ordinary Shares""
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
beneficially owned financial
"may be deemed to be beneficially owned by the Reporting Person"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
pecuniary interest financial
"other than to the extent that she may have a pecuniary interest therein"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →

FAQ

What does the MDXH Form 3 filing by Hilde Windels show?
The Form 3 shows that director Hilde Windels indirectly holds several share option awards on MDxHealth SA ordinary shares through Hilde Windels BV. These options were granted between 2018 and 2025 and vest or vested around subsequent annual general shareholders' meetings.

How many MDxHealth (MDXH) shares are covered by Hilde Windels’ options?
The filing lists options over 42,000 ordinary shares of MDxHealth SA. These consist of two grants of 1,000 shares each and larger grants of 30,000 and 10,000 shares, each with its own exercise price and expiration date as disclosed.

What are the exercise prices of the MDXH options held by Hilde Windels BV?
The options cover ordinary shares at €49.70, €12.80, $2.62, and $2.18 per share. Each price corresponds to a specific grant year, with later grants generally having lower U.S. dollar exercise prices and longer expiration dates.

When do the MDxHealth (MDXH) options reported on Form 3 expire?
The reported share options expire on June 1, 2028, July 1, 2029, June 22, 2034, and June 27, 2035. These staggered expiration dates reflect different grant years and provide a multi-year window during which the options may be exercised.

Does Hilde Windels directly own the MDXH options listed in the Form 3?
The options are held by Hilde Windels BV, and may be deemed beneficially owned by Hilde Windels as its managing director. The filing states she disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Windels Hilde
(Last)(First)(Middle)
CAP BUSINESS CENTER
ZONE INDUSTRIELLE DES HAUTS-SARTS
(Street)
HERSTALBELGIUM4040
(City)(State)(Zip)
BELGIUM
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
MDxHealth SA [ MDXH ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (1)06/01/2028Ordinary Shares1,000(1)IBy Hilde Windels BV(2)
Share Option (3)07/01/2029Ordinary Shares1,000(3)IBy Hilde Windels BV(2)
Share Option (4)06/22/2034Ordinary Shares30,000$2.62IBy Hilde Windels BV(2)
Share Option (5)06/27/2035Ordinary Shares10,000$2.18IBy Hilde Windels BV(2)
Explanation of Responses:
1. Represents options to purchase 1,000 ordinary shares of the Issuer at a price per share of 49.70 Euros granted on June 1, 2018 which vested in full on the date of the annual general shareholders' meeting that took place in the calendar year following the calendar year in which the options were granted.
2. Shares held by Hilde Windels BV may be deemed to be beneficially owned by the Reporting Person as the Managing Director of Hilde Windels BV. The Reporting Person disclaims beneficial ownership of the securities held by Hilde Windels BV other than to the extent that she may have a pecuniary interest therein.
3. Represents options to purchase 1,000 ordinary shares of the Issuer at a price per share of 12.80 Euros granted on July 1, 2019 which vested in full on the date of the annual general shareholders' meeting that took place in the calendar year following the calendar year in which the options were granted.
4. Represents options to purchase 30,000 ordinary shares of the Issuer at a price per share of $2.62 granted on June 22, 2024 which vested in full on the date of the annual general shareholders' meeting that took place in the calendar year following the calendar year in which the options were granted.
5. Represents options to purchase 10,000 ordinary shares of the Issuer at a price per share of $2.18 granted on June 27, 2025 which vest in full on the date of the annual general shareholders' meeting that takes place in the calendar year following the calendar year in which the options were granted.
/s/ Mark Busch, as attorney-in-fact for Hilde Windels04/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR